Search Results - "Sonetto, C"

Novel anti-angiogenic therapeutic strategies in colorectal cancer by Tampellini, M, Sonetto, C, Scagliotti, G V

“…Anti-angiogenetic agents are currently the standard of care in metastatic CRC patients. Bevacizumab, aflibercept, regorafenib and recently ramucirumab have…”
Get more information

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 by Marandino, L., La Salvia, A., Sonetto, C., De Luca, E., Pignataro, D., Zichi, C., Di Stefano, R.F., Ghisoni, E., Lombardi, P., Mariniello, A., Reale, M.L., Trevisi, E., Leone, G., Muratori, L., Marcato, M., Bironzo, P., Novello, S., Aglietta, M., Scagliotti, G.V., Perrone, F., Di Maio, M.

“…Quality of life (QoL) is a relevant end point and a topic of growing interest by both scientific community and regulatory authorities. Our aim was to review…”
Get full text

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial by Lorusso, D., Ferrandina, G., Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M.T., Savarese, A., Tagliaferri, P., Lombardi, D., Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S.C., Maltese, G., Scambia, G.

“…Increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC) is associated with a poor prognosis. Preliminary clinical…”
Get full text

Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review by Brizzi, M P, La Salvia, A, Tampellini, M, Sonetto, C, Volante, M, Scagliotti, G V

“…Everolimus was recently approved for the treatment of neuroendocrine tumors. However, its efficacy and tolerability in hemodialysis patients with end-stage…”
Get full text

Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018 by Lombardi, P., Marandino, L., De Luca, E., Zichi, C., Pignataro, D., Di Stefano, R., Ghisoni, E., Mariniello, A., Reale, M., Trevisi, E., Gianmarco, L., Muratori, L., La Salvia, A., Sonetto, C., Leone, F., Aglietta, M., Novello, S., Scagliotti, G., Perrone, F., Di Maio, M.

Get full text

P-202Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer by Baratelli, C, Sonetto, C, Benedetto, S, Rubatto, E, Di Scipio, F, Pirro, E, Brizzi Maria, P, Di Maio, M, Berta Giovanni, N, Scagliotti Giorgio, V, Tampellini, M

Get full text

Pharmacological bioquivalence of branded and generic oxaliplatin: from preclinical assessment to clinical incidence of hypersensitivity reactions in patients with colorectal cancer by Sonetto, C., Baratelli, C., Brizzi, M.P., Di Maio, M., Scagliotti, G., Tampellini, M.

Get full text

Phase ii study of mytomicin-c plus uft/lv in patients with metastatic colorectal cancer refractory to standard chemotherapy. subgroup analysis of predictive variables in discriminating early progressors by Sonetto, C., Baratelli, C., Brizzi, M.P., Di Maio, M., Scagliotti, G.V., Tampellini, M.

Get full text

A systematic review of the safety profile of bolus, continuous infusion of 5-fu and capecitabine in combination with oxaliplatin in the treatment of colorectal cancer patients by Chiara, B., Zichi, C., Di Maio, M., Sonetto, C., Brizzi, M.P., Scagliotti, G.V., Tampellini, M.

Get full text

Clinical characteristics of a series of patients with prolonged clinical benefit after anti-EGFR treatment in metastatic colorectal cancer by Ponzetti, A., Sonetto, C., Spadi, R., Pinta, F., Fanchini, L., Zanini, M., Ciuffreda, L., Racca, P.

Get full text

Treatment of patients with metastatic colorectal cancer in a real-word scenario: probability of being submitted and clinical benefit of second and further lines of therapy by Brizzi, M.P., Baratelli, C., Di Maio, M., Sonetto, C., Bironzo, P., La Salvia, A., Scagliotti, G.V., Tampellini, M.

Get full text

Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy by Bossi, P., Botta, L., Bironzo, P., Sonetto, C., Musettini, G., Sbrana, A., Di Giannantonio, V., Locati, L., Di Maio, M., Antonuzzo, A.

Get full text

P-108Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018 by Lombardi, P, Marandino, L, De Luca, E, Zichi, C, Pignataro, D, Di Stefano, R, Ghisoni, E, Mariniello, A, Reale, M, Trevisi, E, Gianmarco, L, Muratori, L, La Salvia, A, Sonetto, C, Leone, F, Aglietta, M, Novello, S, Scagliotti, G, Perrone, F, Di Maio, M

Get full text

Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy by Antonuzzo, A., Bossi, P., Botta, L., Bironzo, P., Sonetto, C., Musettini, G., Sbrana, A., Di Giannantonio, V., Locati, L., Di Maio, M.

Get full text

Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer by Tampellini, M., La Salvia, A., Baratelli, C., Di Scipio, F., Pirro, E., Brizzi, M.P., Sonetto, C., Di Maio, M., Berta, G.N., Scagliotti, G.V.

Get full text

P-202 Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer by Baratelli, C., Sonetto, C., Benedetto, S., Rubatto, E., Di Scipio, F., Pirro, E., Brizzi Maria, P., Di Maio, M., Berta Giovanni, N., Scagliotti Giorgio, V., Tampellini, M.

Get full text